학술논문

Ig Glycosylation in Ulcerative Colitis: It’s Time for New Biomarkers
Document Type
article
Source
Frontiers in Pharmacology, Vol 12 (2021)
Subject
Ulcerative colitis
IBD
Biomarker
anti-TNF
glycosylation
Therapeutics. Pharmacology
RM1-950
Language
English
ISSN
1663-9812
Abstract
Background: Ulcerative colitis (UC) is a chronic relapsing disease, which needs a continue monitoring, especially during biological therapies. An increasing number of patients is treated with anti-Tumor Necrosis factor (TNF) drugs, and current research is focalized to identify biomarkers able to monitor the disease and to predict therapeutic outcome.Methods: We enrolled consecutive UC patients treated with anti-TNF, naïve to biologic drugs. Therapeutic outcome was evaluated after 54 weeks of treatment in terms of clinical remission (Partial Mayo Score -PMS-